Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 5, 2005, Pages 955-961

  Palareti, Gualtiero ^a   Legnani, C ^a   Cosmi, B ^a   Guazzaloca, G ^a   Cini, M ^a   Mattarozzi, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Monitoring; Quality; Recurrence; Thrombosis; Venous thromboembolism; Warfarin

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ACENOCOUMAROL; ANTICOAGULANT AGENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; ALGORITHM; BIOSYNTHESIS; LUNG EMBOLISM; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; RECURRENT DISEASE; REGRESSION ANALYSIS; RISK; THROMBOEMBOLISM; TIME; VEIN THROMBOSIS;

ACENOCOUMAROL; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RECURRENCE; REGRESSION ANALYSIS; RISK; RISK FACTORS; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 23844469227     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01330.x     Document Type: Article

References (29)

1. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.
2. Palareti G, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo A, Pengo V, Moia M, Coccheri S. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84: 805-10.
3. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
4. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
5. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-74.
6. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism - A population-based cohort study. Arch Intern Med 2000; 160: 761-8.
7. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-6.
8. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
9. Piovella F, Crippa L, Barone M, Vigano D'Angelo S, Serafini S, Galli L, Beltrametti C, D'Angelo A. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis. Haematologica 2002; 87: 515-22.
10. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-60.
11. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: High negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12.
12. Palareti G, Legnani C, Cosmi B, Valdrè L, Lunghi B, Bernardi F, Coccheri S. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-8.
13. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071-4.
14. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
15. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Warfarin Optimal Duration Italian Trial Investigators. Three months vs. one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-9.
16. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony S, Sanson C, Boissel JP. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453-60.
17. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG. Effect of computer-aided management on the quality of treatment in anti-coagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 2001;86:1060-70.
18. Rosendaal FR, Cannegieter SC, Van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-7.
19. Prandoni P, Cogo A, Bernardi E, Villalta S, Polistena P, Simioni P, Noventa F, Benedetti L, Girolami A. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993; 88: 1730-5.
20. Legnani C, Cosmi B, Cini M, Frascaro M, Guazzaloca G, Palareti G. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004; 124: 504-10.
21. Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med 2003; 349: 1247-56.
22. Gallus A, Jackaman J, Tillet J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; ii: 1293-6.
23. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-4.
24. Brandjes DPM, Heijboer H, Buller HR, Derijk M, Jagt H, Ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-9.
25. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996; 156: 1677-81.
26. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med 1997; 157: 2317-21.
27. Anand SS, Bates S, Ginsberg JS, Levine M, Buller H, Prins M, Haley S, Kearon C, Hirsh J, Gent M. Recurrent venous thrombosis and heparin therapy - an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999; 159: 2029-32.
28. Palareti G, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Leali N, Poggi M, Legnani C, Coccheri S, Musolesi S. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study. Thromb Haemost 1997; 78: 1438-43.
29. Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000; 160: 3431-6.